TFXTeleflex Incorporated
Price
+2.9%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growth steady, the market undecided.
Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products to hospitals and healthcare providers worldwide through a combination of our direct sales force and distributors.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Teleflex Incorporated (TFX) reported revenue of $570M in Q2 2026 (quarter ended Jun 30, 2026), up 29% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $100M (17% of revenue). For the full year FY2025, revenue was $1.99B (+17% year on year) and net income −$906M. Its largest product in Q2 2026 was Vascular Access at $246M, 43% of the disclosed total, ahead of Interventional at 37%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 9, 2026On September 8, 2026, the Board of Directors (the “Board”) of Teleflex Incorporated (the “Company”), upon the recommendation of the Nominating and Governance Committee of the Board, approved an increase in the size of the Board from eight to nine directors and elected Sean M. Salmon to the Board to fill the vacancy …Director or officer change · Form 8-K
- Aug 7, 2026On August 7, 2026, Teleflex Incorporated (the “Company”) entered into an accelerated share repurchase program (the “ASR Transaction”) with Truist Bank (the “Counterparty”) to repurchase an aggregate of $250 million (the “Repurchase Price”) of the Company’s common stock, par value $1.00 per share (the “Common Stock”)Other event · Form 8-K
- Aug 6, 2026Teleflex Reports Second Quarter Finan cial Results and Full Year 2026 Outlook.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $570.3MThe company’s own SEC segment disclosure.
- Vascular Access$246.3M43%
- Interventional$211.9M37%
- Surgical$112.1M20%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #10 of 21 by RyuScore